Carl Dambkowski Sells 5,500 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $84.14, for a total transaction of $462,770.00. Following the sale, the insider owned 207,023 shares of the company’s stock, valued at approximately $17,418,915.22. The trade was a 2.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, April 1st, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $84.84, for a total transaction of $466,620.00.
• On Wednesday, March 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $71.06, for a total transaction of $390,830.00.

Apogee Therapeutics Stock Performance

Shares of APGE opened at $83.03 on Friday. The firm has a market cap of $5.14 billion, a price-to-earnings ratio of -19.68 and a beta of 0.69. Apogee Therapeutics Inc. has a fifty-two week low of $34.34 and a fifty-two week high of $95.32. The firm has a 50 day moving average price of $79.69 and a 200-day moving average price of $73.01.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.02. As a group, equities research analysts predict that Apogee Therapeutics Inc. will post -4.57 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Rockefeller Capital Management L.P. purchased a new position in shares of Apogee Therapeutics in the fourth quarter worth $25,000. Los Angeles Capital Management LLC purchased a new stake in Apogee Therapeutics in the 4th quarter worth approximately $37,000. ANTIPODES PARTNERS Ltd lifted its holdings in Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after buying an additional 246 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Apogee Therapeutics in the 4th quarter worth approximately $136,000. Finally, Ensign Peak Advisors Inc purchased a new stake in Apogee Therapeutics in the 4th quarter worth approximately $170,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on APGE shares. Canaccord Genuity Group boosted their price objective on shares of Apogee Therapeutics from $89.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Royal Bank Of Canada lowered their price objective on shares of Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating for the company in a report on Monday, March 2nd. BTIG Research restated a “buy” rating and issued a $137.00 price objective on shares of Apogee Therapeutics in a report on Monday, March 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Apogee Therapeutics in a report on Monday, April 20th. Finally, Truist Financial assumed coverage on shares of Apogee Therapeutics in a report on Tuesday, March 17th. They issued a “hold” rating and a $83.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Apogee Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $112.73.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.